Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  OTC Bulletin Board  >  La Jolla Pharmaceutical Company    

LA JOLLA PHARMACEUTICAL COMPANY
Mes dernières consult.
Most popular
  Report  
SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

LA JOLLA PHARMACEUTICAL COMPANY : REVERSE SPLIT: 1 of 50

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/14/2014 CEST
A split is applied today to La Jolla Pharmaceutical Company's stock price.


© Factset 2014
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on LA JOLLA PHARMACEUTICAL CO
03/27LA JOLLA PHARMACEUTICAL COMPANY : Announces Launch of GIAPREZA in the United Sta..
AQ
03/22La Jolla Pharmaceutical Company Announces Launch of GIAPREZA™ (angioten..
GL
03/19LA JOLLA PHARMACEUTICAL COMPANY : Announces Pricing of Public Offering of Common..
AQ
03/19LA JOLLA PHARMACEUTICAL COMPANY : Announces $100 Million Public Offering of Comm..
AQ
03/19LA JOLLA PHARMACEUTICAL CO : Entry into a Material Definitive Agreement, Financi..
AQ
03/15La Jolla Pharmaceutical Company Announces Pricing of Public Offering of Commo..
GL
03/14La Jolla Pharmaceutical Company Announces $100 Million Public Offering of Com..
GL
03/06GIAPREZA™ (angiotensin II) Significantly Improved Survival and Reduced ..
GL
02/27LA JOLLA PHARMACEUTICAL COMPANY : - GIAPREZA Significantly Improved Survival of ..
AQ
02/25GIAPREZA™ (angiotensin II) Significantly Improved Survival of Patients ..
GL
More news
Financials ($)
Sales 2018 26,9 M
EBIT 2018 -133 M
Net income 2018 -132 M
Finance 2018 88,5 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 26,2x
EV / Sales 2019 6,76x
Capitalization 794 M
Chart LA JOLLA PHARMACEUTICAL CO
Duration : Period :
La Jolla Pharmaceutical Co Technical Analysis Chart | US5034596040 | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus HOLD
Number of Analysts 6
Average target price 58,5 $
Spread / Average Target 88%
EPS Revisions
Managers
NameTitle
George Francis Tidmarsh President, CEO, Secretary & Director
Kevin C. Tang Chairman
Jennifer Carver Chief Operating Officer
Dennis M. Mulroy Chief Financial & Accounting Officers
Lakhmir S. Chawla Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
LA JOLLA PHARMACEUTICAL COMPANY794
GILEAD SCIENCES5.35%98 675
VERTEX PHARMACEUTICALS10.10%41 476
REGENERON PHARMACEUTICALS-14.19%34 613
GENMAB15.65%12 876
BEIGENE LTD (ADR)73.08%9 059